Delivery of a retroviral vector expressing human β-glucuronidase to the liver and spleen decreases lysosomal storage in Mucopolysaccharidosis VII mice

Molecular Therapy

Volumn 2, Issue 3, 2000, Pages 233-244

  Gao, Cuihua ^a   Sands, Mark S ^a   Haskins, Mark E ^b   Ponder, Katherine Parker ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^c Box 8125 ^*  (United States)

Author keywords

Gene therapy; Glycosaminoglycans; Hepatocyte growth factor; Liver; Lysosomal storage; Retroviral vector; Spleen; glucuronidase

Indexed keywords

MURINAE;

BETA GLUCURONIDASE; PRIMER DNA; SCATTER FACTOR;

ANIMAL; ARTICLE; CELL DIVISION; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; GENE VECTOR; GENETICS; HUMAN; LIVER; LYSOSOME; METABOLISM; MOUSE; MUCOPOLYSACCHARIDOSIS TYPE 7; NUCLEOTIDE SEQUENCE; RETROVIRUS; SPLEEN;

ANIMALS; BASE SEQUENCE; CELL DIVISION; DNA PRIMERS; GENETIC VECTORS; GLUCURONIDASE; HEPATOCYTE GROWTH FACTOR; HUMANS; LIVER; LYSOSOMES; MICE; MUCOPOLYSACCHARIDOSIS VII; RETROVIRIDAE; SPLEEN;

EID: 0034266004     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0121     Document Type: Article

References (56)

1. Meikle, P. J., Hopwood, J. J., Clague, A. E., and Carey, W. F. (1999). Prevalence of lysosomal storage disorders. JAMA 281: 249-254.
2. Birkenmeier, E. H., et al. (1989). Murine mucopolysaccharidosis type VII. Characterization of a mouse with b-glucuronidase deficiency. J. Clin. Invest. 83: 1258-1266.
3. Ray, J., Scarpinom V., Laing, C., and Haskins, M. E. (1999). Biochemical basis of the beta-glucuronidase gene defect causing canine mucopolysaccharidosis VII. J. Hered. 90: 119-123.
4. Fyfe, J. C., et al. (1999). Molecular basis of feline beta-glucuronidase deficiency: An animal model of mucopolysaccharidosis VII. Genomics 58: 121-128.
5. Sands, M. S., and Birkenmeier, E. H. (1993). A single-base-pair deletion in the beta-glucuronidase gene accounts for the phenotype of murine mucopolysaccharidosis type VII. Proc. Natl. Acad. Sci. USA 90: 6567-6571.
6. Sands, M. S., et al. (1997). Murine mucopolysaccharidosis type VII: Long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. J. Clin. Invest. 99: 1596-1605.
7. Vogler, C., Sands, M. S., Levy, B., Calvin, N., Birkenmeier, E. H., and Sly, W. S. (1996). Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: Impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival. Pediatr. Res. 39: 1050-1054.
8. Vogler, C., et al. (1993). Enzyme replacement with recombinant beta-glucuronidase in the newborn mucopolysaccharidosis type VII mouse. Pediatr. Res. 34: 837-840.
9. Soper, B. W., Pung, A. W., Vogler, C. A., Grubb, J. H., Sly, W. S., and Barker, J. E. (1999). Enzyme replacement therapy improves reproductive performance in mucopolysaccharidosis type VII mice but does not prevent postnatal losses. Pediatr. Res. 45: 180-186.
10. Vogler, C., et al. (1998). Murine mucopolysaccharidosis type VII: The impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease. J. Inherit. Metab. Dis. 21: 575-586.
11. Yamada, Y., et al. (1998). Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant. 21: 629-634.
12. Poorthuis, B. J., Romme, A. E., Willemsen, R., and Wagemaker, G. (1994). Bone marrow transplantation has a significant effect on enzyme levels and storage of glycosaminoglycans in tissues and in isolated hepatocytes of mucopolysaccharidosis type VII mice. Pediatr. Res. 36: 187-193.
13. Soper, B. W., Duffy, T. M., Vogler, C. A., and Barker, J. E. (1999). A genetically myeloablated MPS VII model detects the expansion and curative properties of as few as 100 enriched murine stem cells. Exp. Hematol. 27: 1691-1704.
14. Freeman, B. J., Roberts, M. S., Vogler, C. A., Nicholes, A., Hofling, A. A., and Sands, M. S. (1999). Behavior and therapeutic efficacy of beta-glucuronidase-positive mononuclear phagocytes in a murine model of mucopolysaccharidosis type VII. Blood 94: 2142-2150.
15. Wolfe, J. H., et al. (1992). Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature 360: 749-753.
16. Marechal, V., Naffakh, N., Danos, O., and Heard, J. M. (1993). Disappearance of lysosomal storage in spleen and liver of mucopolysaccharidosis VII mice after transplantation of genetically modified bone marrow cells. Blood 82: 1358-1365.
17. Stein, C. S., Ghodsi, A., Derksen, T., and Davidson, B. L. (1999). Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J. Virol. 73: 3424-3429.
18. Ohashi, T., Watabe, K., Uehara, K., Sly, W. S., Vogler, C., and Eto, Y. (1997). Adenovirus-mediated gene transfer and expression of human beta-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice. Proc. Natl. Acad. Sci. USA 94: 1287-1292.
19. Moullier, P., Bohl, D., Heard, J. M., and Danos, O. (1993). Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts. Nat. Genet. 4: 154-159.
20. Moullier, P., Bohl, D., Cardoso, J., Heard, J. M., and Danos, O. (1995). Long-term delivery of a lysosomal enzyme by genetically modified fibroblasts in dogs. Nat. Med. 1: 353-357.
21. Watson, G. L., et al. (1998). Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Gene Ther. 5: 1642-1649.
22. Daly, T. M., Okuyama, T., Vogler, C., Haskins, M. E., Muzyczka, N., and Sands, M. S. (1999). Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. Hum. Gene Ther. 10: 85-94.
23. Daly, T. M., Vogler, C., Levy, B., Haskins, M. E., and Sands, M. S. (1999). Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc. Natl. Acad. Sci. USA 96: 2296-2300.
24. Le, M. T., et al. (1997). Therapeutic levels of functional human Factor X in rats after retroviral-mediated hepatic gene therapy. Blood 89: 1254-1259.
25. Okuyama, T., et al. (1996). Liver-directed gene therapy: A retroviral vector with a complete LTR and the ApoE enhancer-a1-antitrypsin promoter dramatically increases expression of human a1-antitrypsin in vivo. Hum. Gene Ther. 7: 637-645.
26. Cai, S. R., Kennedy, S. C., Bowling, W. M., Flye, M. W., and Ponder, K. P. (1998). Therapeutic levels of functional human protein C in rats after retroviral vector-mediated hepatic gene therapy. J. Clin. Invest. 101: 2831-2841.
27. Gao, C., Jokerst, R., Gondipalli, P., Cai, S.-R., Kennedy, S., and Ponder, K. P. (1999). Intramuscular injection of an adenoviral vector expressing hepatocyte growth factor facilitates hepatic transduction with a retroviral vector in mice. Hum. Gene Ther. 10: 911-922.
28. Gao, C., Jokerst, R., Cai, S. R., Kennedy, S. C., Flye, M. W., and Ponder, K. P. (1999). Lipopolysaccharide potentiates the effect of hepatocyte growth factor upon hepatocyte replication in rats by augmenting AP-1 DNA binding activity. Hepatology 30:1405-1416.
29. Bosch, A., et al. (1996). Proliferation induced by keratinocyte growth factor enhances in vivo retroviral vector-mediated gene transfer to mouse hepatocytes. J. Clin. Invest. 98: 2683-2687.
30. Patijn, G. A., Lieber, A., Schowalter, D. B., Schwall, R., and Kay, M. A. (1998). Hepatocyte growth factor induces hepatocyte proliferation in vivo and allows for efficient retroviral-mediated gene transfer in mice. Hepatology 28: 707-716.
31. Kosai, K-I., et al. (1998). Retrovirus-mediated in vivo gene transfer in the replicating liver using recombinant hepatocyte growth factor without liver injury of partial hepatectomy. Hum. Gene Ther. 9: 1293-1301.
32. Oshima, A., et al. (1987). Cloning, sequencing, and expression of cDNA for human beta-glucuronidase. Proc. Natl. Acad. Sci. USA 84: 685-689.
33. Markowitz, D., Goff, S., and Bank, A. (1988). A safe packaging line for gene transfer: Separating viral genes on two different plasmids. J. Virol. 62: 1120-1124.
34. Markowitz, D., Goff, S., and Bank, A. (1988). Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167: 400-409.
35. Wolfe, J. H., Kyle, J. W., Sands, M. S., Sly. W. S., Markowitz, D. G., and Parente, M. K. (1995). High level expression and export of beta-glucuronidase from murine mucopolysaccharidosis VII cells corrected by a double-copy retrovirus vector. Gene Ther. 2: 70-78.
36. Wolfe, J. H., and Sands, M. S. (1996). Murine mucopolysaccharidosis type VII: A model system for somatic gene therapy of the central nervous system. In Protocols for Gene Transfer in Neuroscience: Toward Gene Therapy of Neurological Disorders (P. R. Lowenstein and L. W. Enquist, Eds.), pp. 264-274. Wiley, New York.
37. Bowles, N. E., Eisensmith, R. C., Mohuiddin, R., Pyron, M., and Woo, S. L. (〈Q2〈). A simple and efficient method for the concentration and purification of recombinant retrovirus for increased hepatocyte transduction in vivo. Hum. Gene Ther. 7: 1735-1742.
38. Alcorn, J. L., Gao, E., Chen, Q., Smith, M. E., Gerard, R. D., and Mendelson, C. R. (1993). Genomic elements involved in transcriptional regulation of the rabbit surfactant protein-A gene. Mol. Endocrinol. 7: 1072-1085.
39. Bowling, W. M., et al. (1996). Portal branch occlusion safely facilitates in vivo retroviral vector transduction of rat liver. Hum. Gene Ther. 7: 2113-2121.
40. Glaser, J. H., and Sly, W. S. (1973). b-Glucuronidase deficiency mucopolysaccharidosis: Methods for enzymatic diagnosis. J. Lab. Clin. Med. 82: 969-977.
41. Björnsson, S. (1993). Simultaneous preparation and quantitation of proteoglycans by precipitation with Alcian blue. Anal. Biochem. 210: 282-291.
42. Rettinger, S., et al. (1994). Liver-directed gene therapy: Quantitative evaluation of promoter elements using in vivo retroviral transduction. Proc. Natl. Acad. Sci. USA 91: 1460-1464.
43. Watson, A. J., Hogan, A., Hahnel, A., Wiemer, K. E., and Schultz, G. A. (1992). Expression of growth factor ligand and receptor genes in the preimplantation bovine embryo. Mol. Reprod. Dev. 31: 87-95.
44. Achord, D. T., Brot, F. E., Bell, C. E., and Sly, W. S. (1978). Human b-glucuronidase: In vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 15: 269-278.
45. Achord, D., Brot, F., Gonzalez-Noriega, A., Sly, W., and Stahl, P. (1977). Human b-glucuronidase. II. Fate of infused human placental b-glucuronidase in the rat. Pediatr. Res. 11: 816-822.
46. Takai, K., et al. (1997). Hepatocyte growth factor is constitutively produced by human bone marrow stromal cells and indirectly promotes hematopoiesis. Blood 89: 1560-1565.
47. Beilmann, M., Odenthal, M., Jung, W., Vande Woude, G. F., Dienes, H. P., and Schirmacher, P. (1997). Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. Blood 90: 4450-4458.
48. Morimoto, A., et al. (1991). Hepatocyte growth factor modulates migration and proliferation of human microvesicular endothelial cells in culture. Biochem. Biophys. Res. Commun. 179: 1042-1049.
49. Lozier, J., Metzger, M., Donahue, R., and Morgan, R. A. (1999). Adenovirus-mediated expression of human coagulation Factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood 94: 3968-3975.
50. Jenks, S. (2000). Gene therapy death - "Everyone has to share in the guilt." J. Natl. Cancer Inst. 92: 98-100.
51. Moskalenko, M., et al. (2000). Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: Implications for gene therapy and virus structure. J. Virol. 74: 1761-1766.
52. Naldini, L., et al. (1996). Gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
53. Kafri, T., Blomer, U., Peterson, D. A., Gage, F. H., and Verma, I. M. (1997). Sustained expression of genes delivered into liver and muscle by lentiviral vectors. Nat. Genet. 17: 314-317.
54. Park, F., Ohashi, K., Chiu, W., Naldini, L., and Kay, M. A. (2000). Efficient lentiviral transduction of liver requires cell cycling in vivo. Nat. Genet. 24: 49-52.
55. Kaido, T., et al. (1997). Continuous hepatocyte growth factor supply prevents lipopolysaccharide-induced liver injury in rats. FEBS Lett. 411: 378-382.
56. Kosai, K., Matsumoto, K., Funakoshi, H., and Nakamura, T. (1999). Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology 30: 151-159.